L Wettergren1, M Sprangers, M Björkholm, A Langius-Eklöf. 1. Department of Neurobiology, Care Sciences and Society, Division of Nursing, Karolinska Institutet, Stockholm, Sweden. lena.wettergren@ki.se
Abstract
OBJECTIVE: The aim was to prospectively measure quality of life in patients with malignant blood disorders following stem cell transplantation (SCT) using an individualized and a standardized measure. METHODS: Twenty-two consecutive patients were assessed before and one year following SCT, using a generic and disease-related version of the Schedule for the Evaluation of Individual Quality of Life-Direct Weighting (SEIQoL-DW) and the EORTC QLQ-C30. Results of the QLQ-C30 were compared with Swedish norm values. RESULTS: A majority of the patients reported concerns related to health before as well as one year after SCT, recorded by both instruments. Mean scores produced by the SEIQoL-DW, and four scales of the EORTC QLQ-C30, showed a change over time, indicating improved quality of life one year after SCT. In comparison with Swedish norm values for the EORTC QLQ-C30, SCT recipients reported a worse functioning. CONCLUSIONS: In addition to well-known disease and treatment-related problems, areas not typically included in standardized instruments were nominated in the disease-related SEIQoL-DW. Such areas included positive aspects, e.g. a changed view of life and oneself. The results support the use of the generic and disease-related SEIQoL-DW to achieve a comprehensive picture of patient's clinical situation under treatment or when recovering from illness. Copyright 2007 John Wiley & Sons, Ltd.
OBJECTIVE: The aim was to prospectively measure quality of life in patients with malignant blood disorders following stem cell transplantation (SCT) using an individualized and a standardized measure. METHODS: Twenty-two consecutive patients were assessed before and one year following SCT, using a generic and disease-related version of the Schedule for the Evaluation of Individual Quality of Life-Direct Weighting (SEIQoL-DW) and the EORTC QLQ-C30. Results of the QLQ-C30 were compared with Swedish norm values. RESULTS: A majority of the patients reported concerns related to health before as well as one year after SCT, recorded by both instruments. Mean scores produced by the SEIQoL-DW, and four scales of the EORTC QLQ-C30, showed a change over time, indicating improved quality of life one year after SCT. In comparison with Swedish norm values for the EORTC QLQ-C30, SCT recipients reported a worse functioning. CONCLUSIONS: In addition to well-known disease and treatment-related problems, areas not typically included in standardized instruments were nominated in the disease-related SEIQoL-DW. Such areas included positive aspects, e.g. a changed view of life and oneself. The results support the use of the generic and disease-related SEIQoL-DW to achieve a comprehensive picture of patient's clinical situation under treatment or when recovering from illness. Copyright 2007 John Wiley & Sons, Ltd.
Authors: Heather S L Jim; Bryan Evans; Jiyeon M Jeong; Brian D Gonzalez; Laura Johnston; Ashley M Nelson; Shelli Kesler; Kristin M Phillips; Anna Barata; Joseph Pidala; Oxana Palesh Journal: Biol Blood Marrow Transplant Date: 2014-04-18 Impact factor: 5.742
Authors: Fawwaz Alaloul; Dorothy Y Brockopp; Michael A Andrykowski; Lynne A Hall; Taghreed S Al Nusairat Journal: Support Care Cancer Date: 2015-01-06 Impact factor: 3.603
Authors: Lisa Brice; Nicole Gilroy; Gemma Dyer; Masura Kabir; Matt Greenwood; Stephen Larsen; John Moore; John Kwan; Mark Hertzberg; Louisa Brown; Megan Hogg; Gillian Huang; Jeff Tan; Christopher Ward; David Gottlieb; Ian Kerridge Journal: Support Care Cancer Date: 2016-10-03 Impact factor: 3.603
Authors: Elsbeth F Taminiau-Bloem; Mechteld R M Visser; Carol Tishelman; Margot A Koeneman; Florence J van Zuuren; Mirjam A G Sprangers Journal: Qual Life Res Date: 2010-01-03 Impact factor: 4.147